Fanapt OK'd for Bipolar; First Depression App Cleared; Keto Diet for Schizophrenia

The FDA approved iloperidone (Fanapt) for the acute treatment of manic or mixed episodes in adults with bipolar I disorder, said maker Vanda Pharmaceuticals. The agent was first approved in 2009 for schizophrenia.

In other regulatory news, the FDA cleared CT-152 (Rejoyn), the first prescription digital treatment for major depressive disorder delivered as a smartphone app, as an adjunct to antidepressants for people ages 22 and older, Otsuka Pharmaceutical and Click Therapeutics announced.

Pets may help slow cognitive decline in older adults, the American Psychiatric Association said.

Deaths by suicide rose from 1999 to 2020 among U.S. adolescents; hanging and asphyxiation suicide deaths had the biggest increase. (JAMA Network Open)

Almost 10% of patients taking amphetamine and dextroamphetamine (Adderall) are affected by a shortage of the drug. (CNN)

Sports gamblers were more likely to say they also binge drank compared with non-gamblers and non-sports bettors in a survey of over 4,300 U.S. adults. (JAMA Network Open)

A Swedish study found high levels of glucose and triglycerides and a low level of high-density lipoprotein were linked with an increased risk of subsequently developing depression, anxiety, and stress-related disorders. (JAMA Network Open)

A 4-month pilot trial found an average 32% improvement in schizophrenia symptoms with a ketogenic diet. (Psychiatry Research)

And another pilot study reported that some dogs can detect stress-related compounds in the breath of people with a history of trauma. (Frontiers in Allergy)

House Republicans called for a probe into unspent mental health funds intended for emergency pandemic response and for the 988 crisis hotline. (Washington Post)

Comment